On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has shown promising results in a Phase 3 trial for treating chronic spontaneous ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy ...

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved ...

Sanofi's existing product line boasts several top-tier drugs, including immunology drug Dupixent, an IL-4/IL-13 inhibitor. Dupixent looks well positioned to reach peak sales of over EUR 18 billion ...

Sanofi markets Dupixent in partnership with Regeneron REGN. While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.

while we saw steady growth of 67% for our launch medicines as well as volume-driven growth by Dupixent," CEO Paul Hudson remarked. Sanofi's (SNY) bottom line improved ~12% YoY to €2.86 earnings ...

Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company reported third-quarter sales of 13.44 billion euros or $14.79 billion, beating the consensus of $13. ...